This medical diagnostics stock is ready for a big move higher, charts show

NTRA is a medical diagnostics company that makes DNA blood tests to help doctors detect health problems early. This includes cancer, pregnancy complications, and organ transplant issues, often before symptoms appear. Chart-wise, the stock is attempting to leverage a long trading range — a similar scenario to IHI discussed last week — though the pattern here is noticeably larger. Indeed, there have been plenty of whipsaws since its strong uptrend ended at the start of the year. Over the last few months, however, momentum has improved, and we can see a clear progression of higher lows and higher highs developing. Thus, the stock could be getting ready to take the next step and break out. If it can, the measured-move target would be near 263, with a stop loss at 203. Bigger picture, going back over the last three years, it's clear that the stock has been in an uptrend for the majority of that period, with its strongest advances occurring after bouncing from the uptrend line shown. Each of the four prior tests of that line produced immediate upside follow-through, with some rallies lasting for months before the next consolidation phase began. With NTRA only a few weeks removed from another successful test of that trendline, it could still be in the early stages of yet another multi-month advance. As the chart shows, the bounce from last summer eventually carried the stock back to a key resistance area in the fall of last year. …